Work

Sp200a Subcutaneously Administered Investigational Rnai Therapeutic (aln-cc5) Targeting Complement C5 for Treatment of Pnh and Complement-mediated Diseases:interim Phase 1 Study Results

Year: 2016

Type: conference-abstract

Source: Nephrology Dialysis Transplantation

DOI: 10.1093/ndt/gfw162.19

Authors: Nader Najafian, Anita Hill, Jorg Taubel, Jim Bush, Anna Borodovsky, Noriyuki Kawahata, Helen Mclean, Angela Partisano, Prasoon Chaturvedi, Benny Sorensen

Institutions: Alnylam Pharmaceuticals (United States), Leeds Teaching Hospitals NHS Trust, St George's, University of London, Covance (United Kingdom)

Language: English

Topic: Complement system in diseases

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2588616790

Cites:

Cited by: 1

Related to: 10